HK1199252A1 - Inhibitors of nedd8-activating enzyme - Google Patents

Inhibitors of nedd8-activating enzyme Download PDF

Info

Publication number
HK1199252A1
HK1199252A1 HK14112794.7A HK14112794A HK1199252A1 HK 1199252 A1 HK1199252 A1 HK 1199252A1 HK 14112794 A HK14112794 A HK 14112794A HK 1199252 A1 HK1199252 A1 HK 1199252A1
Authority
HK
Hong Kong
Prior art keywords
nedd8
inhibitors
activating enzyme
disclosed
chemical entities
Prior art date
Application number
HK14112794.7A
Other languages
English (en)
Chinese (zh)
Inventor
Sue Mccarron Ashley
B. Sells Todd
Stirling Matthew
G. Stroud Stephen
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Publication of HK1199252A1 publication Critical patent/HK1199252A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14112794.7A 2011-08-24 2012-08-23 Inhibitors of nedd8-activating enzyme HK1199252A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24
US201161526830P 2011-08-24
PCT/US2012/052007 WO2013028832A2 (en) 2011-08-24 2012-08-23 Inhibitors of nedd8-activating enzyme

Publications (1)

Publication Number Publication Date
HK1199252A1 true HK1199252A1 (en) 2015-06-26

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112794.7A HK1199252A1 (en) 2011-08-24 2012-08-23 Inhibitors of nedd8-activating enzyme

Country Status (29)

Country Link
US (3) US8809356B2 (enExample)
EP (2) EP2748168A4 (enExample)
JP (1) JP6038150B2 (enExample)
KR (1) KR20140054288A (enExample)
CN (1) CN103889988B (enExample)
AR (1) AR087672A1 (enExample)
AU (1) AU2012298813B2 (enExample)
BR (1) BR112014004239A2 (enExample)
CA (1) CA2846231C (enExample)
CL (1) CL2014000441A1 (enExample)
CO (1) CO6900148A2 (enExample)
CR (1) CR20140128A (enExample)
DO (1) DOP2014000037A (enExample)
EA (1) EA031067B1 (enExample)
EC (1) ECSP14013263A (enExample)
GE (1) GEP201606522B (enExample)
HK (1) HK1199252A1 (enExample)
IL (1) IL231069B (enExample)
MA (1) MA35439B1 (enExample)
MX (1) MX2014002015A (enExample)
MY (1) MY166889A (enExample)
PE (1) PE20141146A1 (enExample)
PH (1) PH12014500419A1 (enExample)
SG (2) SG11201400102WA (enExample)
TN (1) TN2014000080A1 (enExample)
TW (1) TWI577667B (enExample)
UA (1) UA114894C2 (enExample)
UY (1) UY34292A (enExample)
WO (1) WO2013028832A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2015002994A2 (en) * 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
WO2017183927A1 (ko) * 2016-04-20 2017-10-26 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
EP1597255A1 (en) 2002-11-13 2005-11-23 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ME02789B (me) * 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
EP2430026A1 (en) * 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
PL2773360T3 (pl) * 2011-11-03 2018-09-28 Millennium Pharmaceuticals, Inc. Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego

Also Published As

Publication number Publication date
US20180290983A1 (en) 2018-10-11
US20130150388A1 (en) 2013-06-13
US9850214B2 (en) 2017-12-26
EP3323414A1 (en) 2018-05-23
CN103889988A (zh) 2014-06-25
EP2748168A4 (en) 2015-04-22
AU2012298813A1 (en) 2013-05-02
KR20140054288A (ko) 2014-05-08
TN2014000080A1 (en) 2015-07-01
WO2013028832A2 (en) 2013-02-28
AR087672A1 (es) 2014-04-09
JP6038150B2 (ja) 2016-12-07
GEP201606522B (en) 2016-08-10
CA2846231A1 (en) 2013-02-28
AU2012298813B2 (en) 2016-07-28
EA201400249A1 (ru) 2014-05-30
PH12014500419A1 (en) 2020-06-22
TWI577667B (zh) 2017-04-11
CR20140128A (es) 2014-05-15
BR112014004239A2 (pt) 2017-03-21
MX2014002015A (es) 2014-03-27
CN103889988B (zh) 2018-05-04
PE20141146A1 (es) 2014-09-21
SG11201400102WA (en) 2014-03-28
US20150011572A1 (en) 2015-01-08
CO6900148A2 (es) 2014-03-20
US8809356B2 (en) 2014-08-19
MY166889A (en) 2018-07-24
CA2846231C (en) 2017-06-20
UA114894C2 (uk) 2017-08-28
IL231069B (en) 2018-02-28
IL231069A0 (en) 2014-03-31
ECSP14013263A (es) 2014-04-30
UY34292A (es) 2013-04-05
JP2014524476A (ja) 2014-09-22
MA35439B1 (fr) 2014-09-01
EA031067B1 (ru) 2018-11-30
CL2014000441A1 (es) 2014-09-26
SG10201601023UA (en) 2016-03-30
NZ622220A (en) 2016-04-29
TW201313689A (zh) 2013-04-01
DOP2014000037A (es) 2014-04-15
EP2748168A2 (en) 2014-07-02
WO2013028832A3 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
WO2013028832A3 (en) Inhibitors of nedd8-activating enzyme
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2013163190A8 (en) Dna-pk inhibitors
ZA200906264B (en) Aminopyrimidines useful as inhibitors of protein kinases
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MX2014006027A (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
NZ610713A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
IN2012DN01641A (enExample)
WO2012048259A3 (en) Substituted pyridazine carboxamide compounds
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
IN2012DN01642A (enExample)
MX2010007546A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase